| Literature DB >> 26060351 |
Azusa Takaoka1, Masaya Sasaki2, Mika Kurihara2, Hiromi Iwakawa2, Mai Inoue2, Shigeki Bamba3, Hiromitsu Ban3, Akira Andoh3, Yoshiko Miyazaki4.
Abstract
This study aimed to compare the nutritional status and energy expenditure of hospitalized patients with Crohn's disease (CD) and those with ulcerative colitis (UC). Twenty-two hospitalized patients with CD and 18 patients with UC were enrolled in this study. We analyzed nutritional status upon admission by using nutritional screening tools including subjective global assessment, malnutrition universal screening tool, and laboratory tests. We measured resting energy expenditure (mREE) of the patients with indirect calorimetry and predicted resting energy expenditure (pREE) was calculated by using the Harris-Benedict equation. Results presented here indicate no significant difference in nutritional parameters and energy metabolism between CD and UC patients. In UC patients, a significant correlation was observed between mREE/body weight and disease activity detected by the Lichtiger and Seo indices. However, there was no correlation between mREE/body weight and Crohn's disease activity index in CD patients. Inflammatory cytokine interleukin-6 levels correlated with mREE/pREE in CD and UC patients while tumor necrosis factor-α was not. In conclusion, energy expenditure significantly correlated with disease activity in UC patients but not in CD patients. These results indicate that establishing daily energy requirements based on disease activity of UC is imperative for improving the nutritional status of patients.Entities:
Keywords: Crohn’s disease; energy metabolism; indirect calorimetry; nutritional status; ulcerative colitis
Year: 2015 PMID: 26060351 PMCID: PMC4454083 DOI: 10.3164/jcbn.14-95
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Characteristics of patients with IBD (n = 40)
| Characteristics | CD patients ( | UC patients ( | |
|---|---|---|---|
| Gender (male/female) | 16/6 | 12/6 | |
| Age (years) | 30.8 ± 9.5 | 39.4 ± 16.9 | 0.064 |
| Height (cm) | 168.5 ± 7.5 | 163.5 ± 8.7 | 0.062 |
| Body weight (kg) | 53.0 ± 6.4 | 51.2 ± 8.9 | 0.466 |
| BMI (kg/m2) | 18.7 ± 2.5 | 19.1 ± 2.5 | 0.643 |
| Type of CD (ileal/ileocolitic/colitic) | 6/13/3 | — | |
| Type of UC (total colitis/left-side colitis) | — | 12/6 | |
| Activity index | |||
| CDAI for CD | 255.0 ± 88.7 | — | |
| Seo index for UC | — | 222.2 ± 33.5 | |
| Lichtiger index for UC | — | 11.3 ± 2.8 | |
| Treatments | |||
| PSL ≥20 mg/day | 5 | 16 | |
| <20 mg/day | 17 | 2 | |
| Azathioprine or Cyclosporine | 10 | 12 | |
| Leukocytapheresis | 0 | 10 | |
| Anti-TNF-α | 18 | 2 | |
| Nutritional therapy | |||
| TPN/PPN | 17/5 | 11/7 | 0.267 |
| EN (switched from PN) | 21 | — | |
| Surgical operation | 9 | 1 | 0.010 |
| Duration of the disease (years) | 4.6 ± 6.0 | 3.6 ± 6.1 | 0.642 |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; BMI, body mass index; CDAI, Crohn’s Disease Activity Index; PSL, prednisolone; anti-TNF-α, anti-tumor necrosis factor-α; TPN, total parenteral nutrition; PPN, peripheral parenteral nutrition; EN, enteral nutrition; PN, parenteral nutrition. Each value represents the mean ± SD.
Nutritional screening
| CD patients (%) | UC patients (%) | ||
|---|---|---|---|
| SGA | |||
| Well nourished | 4.5 | 0 | 0.545 |
| Moderately malnourished | 54.5 | 66.7 | |
| Severely malnourished | 41.0 | 33.3 | |
| MUST | |||
| Low risk | 13.6 | 11.1 | 0.767 |
| Medium risk | 18.2 | 27.8 | |
| High risk | 68.2 | 61.1 | |
| NRS2002 | |||
| Without nutritional risk | 22.7 | 16.7 | 0.634 |
| With nutritional risk | 77.3 | 83.3 | |
| PNI | |||
| Low risk | 9.1 | 16.7 | 0.471 |
| High risk | 90.9 | 83.3 | |
| CONUT | |||
| Normal | 4.5 | 11.1 | 0.766 |
| Light | 13.6 | 11.1 | |
| Moderate | 45.5 | 33.3 | |
| Severe | 36.4 | 44.5 |
SGA, subjective global assessment; MUST, malnutrition universal screening tool; NRS2002, nutritional risk screening 2002; PNI, prognostic nutritional index; CONUT, controlling nutritional status.
Laboratory tests and inflammatory cytokines
| CD patients | UC patients | ||
|---|---|---|---|
| Laboratory tests | |||
| TP (g/dl) | 6.4 ± 0.8 | 5.8 ± 0.6 | 0.009 |
| Alb (g/dl) | 2.8 ± 0.5 | 2.6 ± 0.6 | 0.234 |
| T-cho (mg/dl) | 127.5 ± 31.8 | 125.9 ± 36.5 | 0.882 |
| TG (mg/dl) | 82.9 ± 31.1 | 90.0 ± 57.5 | 0.292 |
| Hb (g/dl) | 11.0 ± 2.0 | 10.3 ± 3.0 | 0.430 |
| CRP (mg/dl) | 6.6 ± 6.8 | 6.1 ± 5.5 | 0.925 |
| Inflammatory cytokines | |||
| IL-6 (pg/ml) | 13.8 ± 13.4 | 17.0 ± 14.0 | 0.506 |
| TNF-α (pg/ml) | 2.0 ± 0.7 | 2.7 ± 1.7 | 0.108 |
TP, total protein; Alb, albumin; T-cho, total cholesterol; TG, triglyceride; Hb, hemoglobin; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α. Each value represents the mean ± SD.
Energy metabolism
| CD patients | UC patients | ||
|---|---|---|---|
| mREE (kcal/day) | 1,388.7 ± 226.6 | 1,341.6 ± 252.6 | 0.538 |
| pREE (kcal/day) | 1,413.1 ± 127.9 | 1,324.6 ± 174.8 | 0.072 |
| mREE/body weight (kcal/kg/day) | 26.3 ± 3.8 | 26.3 ± 3.0 | 0.986 |
| pREE/body weight (kcal/kg/day) | 26.8 ± 2.1 | 26.1 ± 2.8 | 0.378 |
| mREE/pREE | 0.98 ± 0.13 | 1.01 ± 0.13 | 0.475 |
| RQ | 0.81 ± 0.07 | 0.79 ± 0.09 | 0.377 |
mREE, measured resting energy expenditure; pREE, predicted resting energy expenditure; RQ, respiratory quotient. Each value represents the mean ± SD.
Fig. 1Correlation between measured resting energy expenditure/body weight (mREE/body weight) and Crohn’s Disease Activity Index (CDAI) in CD patients. There was no correlation between mREE/body weight and CDAI in CD patients.
Fig. 2Correlation between measured resting energy expenditure/body weight (mREE/body weight) and the Lichtiger and Seo indices in UC patients. The mREE/body weight in UC patients exhibited positive correlation with both the Lichtiger index (A) and Seo index (B).
Fig. 3Correlation between interleukin-6 (IL-6) levels and tumor necrosis factor-α (TNF-α) levels and measured resting energy expenditure/predicted resting energy expenditure (mREE/pREE) or mREE/body weight in CD patients. IL-6 levels in CD patients exhibited positive correlation with mREE/pREE (A) and mREE/body weight (B). However, there was no significant correlation between TNF-α and mREE/pREE (C) or mREE/body weight (D) in CD patients.
Fig. 4Correlation between interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels and measured resting energy expenditure/predicted resting energy expenditure (mREE/pREE) or mREE/body weight in UC patients. IL-6 levels in UC patients exhibited positibe correlation with mREE/pREE (p = 0.062) (A). However, there was no significant correlation between IL-6 and mREE/body weight (B), or correlation between TNF-α and mREE/pREE (C) or mREE/body weight (D) in UC patients.